Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

466 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials.
Fertitta L, Bergqvist C, Sarin KY, Plotkin SR, Moertel C, Petersen AK, Cannon A, Berman Y, Pichard DC, Röhl C, Lessing A, Brizion B, Peiffer B, Ravaud P, Tran VT, Armand ML, Moryousef S, Ferkal S, Jannic A, Ezzedine K, Wolkenstein P; Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) international collaboration. Fertitta L, et al. Among authors: wolkenstein p. Br J Dermatol. 2024 Jan 23;190(2):216-225. doi: 10.1093/bjd/ljad397. Br J Dermatol. 2024. PMID: 37877514
Methodological innovations and stakeholder involvement in core outcome sets for skin diseases: a survey of the C3 working groups.
Ahmed A, Koza E, Shi V, Ma M, Haq M, Kottner J, Garg A, Ingram JR, Ezzedine K, Spuls PI, Beeckman D, Wolkenstein P, Fransen F, Noe MH, Langbroek GB, Bauer A, Thorlacius L, Horbach SER, Layton A, Apfelbacher C, Cahn BA, Pearlman R, Schlessinger DI, Alam M. Ahmed A, et al. Among authors: wolkenstein p. Arch Dermatol Res. 2024 Mar 18;316(4):109. doi: 10.1007/s00403-023-02812-1. Arch Dermatol Res. 2024. PMID: 38498269 No abstract available.
Muscle involvement in systemic sclerosis: high mortality not associated with nature of histological lesions.
Gouellec NL, Zaidan L, Chaigne B, Periou B, Cailliau E, Dhote R, Riviere S, Uzunhan Y, Agard C, Godeau B, Wolkenstein P, Hachulla E, Mouthon L, Authier J. Gouellec NL, et al. Among authors: wolkenstein p. Rheumatology (Oxford). 2024 Aug 13:keae407. doi: 10.1093/rheumatology/keae407. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 39137158
Comprehensive Catalog of Variants Potentially Associated with Hidradenitis Suppurativa, Including Newly Identified Variants from a Cohort of 100 Patients.
Muret K, Le Goff V, Dandine-Roulland C, Hotz C, Jean-Louis F, Boisson B, Mesrob L, Sandron F, Daian D, Olaso R, Le Floch E, Meyer V, Wolkenstein P, Casanova JL, Lévy Y, Bonnet E, Deleuze JF, Hüe S. Muret K, et al. Among authors: wolkenstein p. Int J Mol Sci. 2024 Sep 26;25(19):10374. doi: 10.3390/ijms251910374. Int J Mol Sci. 2024. PMID: 39408704 Free PMC article.
Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas.
Azizi AA, Hargrave D, Passos J, Wolkenstein P, Rosenbaum T, Santoro C, Rosenmayr V, Pletschko T, Ascierto PA, Hernández HS. Azizi AA, et al. Among authors: wolkenstein p. Neurooncol Pract. 2024 Apr 27;11(5):515-531. doi: 10.1093/nop/npae038. eCollection 2024 Oct. Neurooncol Pract. 2024. PMID: 39279781 Free PMC article. Review.
Prenatal diagnosis for neurofibromatosis type 1 and the pitfalls of germline mosaics.
Pacot L, Vidaud D, Ye M, Chansavang A, Coustier A, Maillard T, Barbance C, Laurendeau I, Hébrard B, Lunati-Rozie A, Funalot B, Wolkenstein P, Vidaud M, Goldenberg A, Morice-Picard F, Hadjadj D, Parfait B, Pasmant E. Pacot L, et al. Among authors: wolkenstein p. NPJ Genom Med. 2024 Sep 8;9(1):41. doi: 10.1038/s41525-024-00425-9. NPJ Genom Med. 2024. PMID: 39245665 Free PMC article.
Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis: A potential model for rare diseases.
Dhaenens BAE, Heimann G, Bakker A, Nievo M, Ferner RE, Evans DG, Wolkenstein P, Leubner J, Potratz C, Carton C, Iloeje U, Kirk G, Blakeley JO, Plotkin S, Fisher MJ, Kim A, Driever PH, Azizi AA, Widemann BC, Gross A, Parke T, Legius E, Oostenbrink R. Dhaenens BAE, et al. Among authors: wolkenstein p. Neurooncol Pract. 2024 Jan 4;11(4):395-403. doi: 10.1093/nop/npae001. eCollection 2024 Aug. Neurooncol Pract. 2024. PMID: 39006526 Free PMC article.
466 results